ReactDx launches sleep monitoring device
By HME News Staff
Updated 9:34 AM CDT, Mon August 5, 2024
MELBOURNE, Fla. – ReactDx, a division of React Health, has launched NiteWatch, a sleep monitoring device that’s cleared by the U.S. Food and Drug Administration. The company says NiteWatch empowers physicians to diagnose and manage sleep apnea in the comfort of the home. "We are thrilled to introduce NiteWatch, a significant step forward in the integration of sleep and cardiac care," said Bill Shoop, CEO of React Health. " We recognize the critical role that sleep health plays in overall well-being, particularly its relationship with cardiac health, and are committed to improving access to essential diagnostic tools. The NiteWatch is designed to complement existing services by offering a different point of entry for patients who might otherwise go undiagnosed.” NiteWatch, which has been validated against polysomnography (PSG) studies for sleep apnea and sleep staging, measures six distinct channels, including SpO2, photoplethysmogram (PPG), pulse rate, airflow, respiratory effort and heart rate variability (HRV). The device is integrated with a mobile app for seamless data transmission. ReactDx was founded in 2022, bringing together several companies in the sleep diagnostics and cardiac monitoring industries with roots dating to 1981.
Comments